Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

Immunomodulatory monoclonal antibodies (mAbs) differ from their tumor-targeting counterparts because they exert therapeutic effects by directly interacting with soluble or (most often) cellular components of the immune system. Besides holding promise for the treatment of autoimmune and inflammatory...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Buqué, Aitziber, Bloy, Norma, Aranda, Fernando, Castoldi, Francesca, Eggermont, Alexander, Cremer, Isabelle, Fridman, Wolf Hervé, Fucikova, Jitka, Galon, Jérôme, Marabelle, Aurélien, Spisek, Radek, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2015
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4485728/
https://ncbi.nlm.nih.gov/pubmed/26137403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1008814
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky